Groupama Asset Managment Has $1.91 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Groupama Asset Managment raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,851,556 shares of the medical device company's stock after purchasing an additional 31,358 shares during the quarter. Groupama Asset Managment owned 0.73% of DexCom worth $1,912,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of DXCM. QRG Capital Management Inc. boosted its holdings in DexCom by 32.6% during the second quarter. QRG Capital Management Inc. now owns 14,449 shares of the medical device company's stock worth $1,638,000 after buying an additional 3,553 shares in the last quarter. Sequoia Financial Advisors LLC increased its holdings in DexCom by 6.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,376 shares of the medical device company's stock valued at $836,000 after acquiring an additional 445 shares in the last quarter. Diversified Trust Co raised its position in shares of DexCom by 1.8% during the 2nd quarter. Diversified Trust Co now owns 60,281 shares of the medical device company's stock worth $6,835,000 after purchasing an additional 1,057 shares during the last quarter. NorthCrest Asset Manangement LLC lifted its stake in DexCom by 11.2% in the 2nd quarter. NorthCrest Asset Manangement LLC now owns 26,076 shares of the medical device company's stock valued at $2,956,000 after buying an additional 2,625 shares in the last quarter. Finally, Financial Insights Inc. acquired a new stake in DexCom during the 2nd quarter valued at $242,000. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Price Performance

Shares of DXCM stock traded up $0.81 during midday trading on Monday, reaching $78.53. 1,129,609 shares of the company were exchanged, compared to its average volume of 3,894,336. The company has a market cap of $30.67 billion, a P/E ratio of 46.47, a PEG ratio of 2.38 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company's 50 day moving average price is $72.55 and its two-hundred day moving average price is $85.74.

Insider Activity

In related news, EVP Sadie Stern sold 4,259 shares of the firm's stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.30% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DXCM. Sanford C. Bernstein boosted their price target on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Piper Sandler reissued an "overweight" rating and set a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. StockNews.com cut DexCom from a "buy" rating to a "hold" rating in a report on Saturday, November 2nd. Leerink Partners lowered their price objective on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Finally, Royal Bank of Canada reduced their target price on DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $101.88.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.